Tomazos I - Search Results

1

Predictors of cardiac disease in duchenne muscular dystrophy: a systematic review and evidence grading.

Landfeldt E, Alemán A, Abner S, Zhang R, Werner C, Tomazos I, Lochmüller H, Quinlivan RM, Wahbi K. Landfeldt E, et al. Among authors: tomazos i. Orphanet J Rare Dis. 2024 Sep 28;19(1):359. doi: 10.1186/s13023-024-03372-x. Orphanet J Rare Dis. 2024. PMID: 39342355 Free PMC article.

2

Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.

Landfeldt E, Alemán A, Abner S, Zhang R, Werner C, Tomazos I, Ferizovic N, Lochmüller H, Kirschner J. Landfeldt E, et al. Among authors: tomazos i. J Neuromuscul Dis. 2024;11(3):579-612. doi: 10.3233/JND-230220. J Neuromuscul Dis. 2024. PMID: 38669554 Free PMC article.

3

Factors Associated with Respiratory Health and Function in Duchenne Muscular Dystrophy: A Systematic Review and Evidence Grading.

Landfeldt E, Aleman A, Abner S, Zhang R, Werner C, Tomazos I, Lochmüller H, Quinlivan RM. Landfeldt E, et al. Among authors: tomazos i. J Neuromuscul Dis. 2024;11(1):25-57. doi: 10.3233/JND-230094. J Neuromuscul Dis. 2024. PMID: 37980679 Free PMC article.

4

The burden of mitochondrial disease with associated seizures: systematic literature reviews of health-related quality of life, utilities, costs and healthcare resource use data.

Bertini E, Gregg E, Bartlett C, Senthilnathan V, Arber M, Watkins D, Graziadio S, Tomazos I. Bertini E, et al. Among authors: tomazos i. Orphanet J Rare Dis. 2023 Oct 11;18(1):320. doi: 10.1186/s13023-023-02945-6. Orphanet J Rare Dis. 2023. PMID: 37821990 Free PMC article. Review.

5

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Schrezenmeier H, Kulasekararaj A, Mitchell L, de Latour RP, Devos T, Okamoto S, Wells R, Popoff E, Cheung A, Wang A, Tomazos I, Patel Y, Lee JW. Schrezenmeier H, et al. Among authors: tomazos i. Ann Hematol. 2024 Jan;103(1):5-15. doi: 10.1007/s00277-023-05483-0. Epub 2023 Oct 7. Ann Hematol. 2024. PMID: 37804344 Free PMC article. Clinical Trial.

6

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.

Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Mauch TJ, et al. Among authors: tomazos i. J Comp Eff Res. 2023 Sep;12(9):e230036. doi: 10.57264/cer-2023-0036. Epub 2023 Jul 29. J Comp Eff Res. 2023. PMID: 37515502 Free PMC article.

7

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States.

Wang Y, Al-Dakkak I, Garlo K, Ong ML, Tomazos I, Mahajerin A. Wang Y, et al. Among authors: tomazos i. Kidney Med. 2023 May 31;5(8):100683. doi: 10.1016/j.xkme.2023.100683. eCollection 2023 Aug. Kidney Med. 2023. PMID: 37415624 Free PMC article.

8

Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.

Cella D, Johansson P, Ueda Y, Tomazos I, Gustovic P, Wang A, Patel AS, Schrezenmeier H. Cella D, et al. Among authors: tomazos i. J Patient Rep Outcomes. 2023 Jul 5;7(1):63. doi: 10.1186/s41687-023-00609-4. J Patient Rep Outcomes. 2023. PMID: 37405515 Free PMC article.

9

[Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].

Ishiyama K, Usuki K, Ikezoe T, Gotoh A, Myren KJ, Tomazos I, Shimono A, Ninomiya H, Sakurai M, Nakao S, Nishimura JI. Ishiyama K, et al. Among authors: tomazos i. Rinsho Ketsueki. 2023;64(1):9-17. doi: 10.11406/rinketsu.64.9. Rinsho Ketsueki. 2023. PMID: 36775313 Japanese.

10

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.

Shammo J, Gajra A, Patel Y, Tomazos I, Kish J, Hill A, Sierra JR, Araten D. Shammo J, et al. Among authors: tomazos i. J Blood Med. 2022 Aug 12;13:425-437. doi: 10.2147/JBM.S361863. eCollection 2022. J Blood Med. 2022. PMID: 35983240 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters